文献速递前列腺增生与排尿功能障碍

水蒸气热疗与药物治疗前列腺增生三年疗效比较:MTOPS队列数据

Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial.
PubMed 文献 · J Urol · 2018-03-01

本研究将Rezūm水蒸气热疗随机对照试验的治疗组与MTOPS研究中多沙唑嗪和/或非那雄胺治疗的1140例患者(前列腺体积30-80cc、IPSS≥13)进行队列比较,随访3年。热疗持续改善症状评分约50%,优于单药治疗,与联合药物相似;峰值流速改善4-5ml/s,在24个月和12个月分别优于非那雄胺和联合药物;任何药物治疗的临床进展率约为单次热疗的5倍。

要点

  • 单次水蒸气热疗在36个月内持续改善症状评分约50%。
  • 热疗症状改善优于多沙唑嗪或非那雄胺单药,与联合药物相似。
  • 热疗后峰值流速改善4-5ml/s,任何药物治疗临床进展率约为热疗的5倍。

核心结论

  • 单次水蒸气热疗可有效且持久地改善症状评分,观察到的临床进展率低于长期每日药物治疗。

研究设计与样本

  • 将Rezūm水蒸气热疗随机对照试验治疗组与MTOPS研究中多沙唑嗪和/或非那雄胺治疗者进行队列比较。
  • 医学治疗组纳入1140例(占原3047例的37.4%),前列腺体积30-80cc且IPSS≥13。
  • 比较3年内的症状变化和临床进展率。

主要发现

  • 热疗在36个月内改善症状评分约50%(p<0.0001)。
  • 症状改善优于任一单药(p≤0.02),与联合药物相似(p=0.73)。
  • 热疗和多沙唑嗪后峰值流速改善4-5ml/s,热疗在24个月和12个月分别优于非那雄胺(p<0.001)和联合药物(p<0.01)。
  • 3年观察到的临床进展率:任何药物治疗约为单次热疗的5倍。

关键数值与推荐

  • 医学治疗组来自MTOPS研究,占原3047例的37.4%(1140例)。
  • 纳入标准:前列腺体积30-80cc,IPSS≥13。
  • 热疗症状评分改善约50%,p<0.0001。
  • 峰值流速改善4-5ml/s。
  • 临床进展率:任何药物治疗约为单次热疗的5倍。

临床怎么用

  • 对于前列腺体积30-80cc且IPSS≥13的BPH患者,单次水蒸气热疗可作为长期药物治疗的替代选择。
  • 热疗在症状改善上优于单药,与联合药物相当,且临床进展率更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the long-term outcomes of treatment of lower urinary tract symptoms due to benign prostatic hyperplasia to compare a 1-time water vapor thermal therapy procedure with daily medical therapy in cohorts from the MTOPS (Medical Therapy of Prostatic Symptoms) study. MATERIALS AND METHODS: Results in the treatment arm of a randomized, controlled trial of thermal therapy using the Rezūm® System were compared to MTOPS subjects treated with doxazosin and/or finasteride. Evaluations were restricted to medical therapy subjects, representing 1,140 of the original 3,047 (37.4%), with a prostate volume of 30 to 80 cc and an International Prostate Symptom Score of 13 or greater to include men who met key criteria of the Rezūm and MTOPS trials. Outcomes were compared during 3 years for symptom changes and clinical progression rates. RESULTS: Thermal therapy improved symptom scores by approximately 50% throughout 36 months (p <0.0001). Symptom improvement was greater than with either drug alone but similar to that of combination drugs (p ≤0.02 and 0.73, respectively). The peak flow rate improved 4 to 5 ml per second after thermal therapy and doxazosin while thermal therapy was superior to finasteride and combination drugs for 24 and 12 months (p <0.001 and <0.01, respectively). Observed rates of clinical progression during 3 years corroborate these outcomes with approximately 5 times greater progression for any medical therapy vs a single thermal therapy procedure. CONCLUSIONS: A single water vapor thermal therapy procedure provided effective and durable improvements in symptom scores with lower observed clinical progression rates compared to daily long-term use of pharmaceutical agents.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Gupta N, Rogers T, Holland B, et al. Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. J Urol. 2018. PMID: 29499208. doi:10.1016/j.juro.2018.02.3088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。